Autor(es): Pritchard Jane

Resumo: Guillain-Barré syndrome (GBS) is a clinical diagnosis, with progressive weakness and areflexia evolving over less than four weeksAntiganglioside antibodies are present in 25% of patients with typical acute demyelinating GBS; in Miller-Fisher syndrome 95% of patients possess antibodies against GQ1b gangliosideMore than 10 white cells in cerebrospinal fluid should raise concern of alternative diagnoses including HIVEmergency management must include vital capacity and cardiac monitoring, together with early intubation for patients with declining respiratory and bulbar functionStandard treatment is intravenous immunoglobulin 0.4 g/kg/day for five days in non-ambulant patients.Guillain-Barré syndrome (GBS), with an annual incidence of 1-2 per 100,000, is the most common cause of neuromuscular paralysis in the western world. Even with modern intensive care and intravenous (iv) immunoglobulin (Ig) treatment there remains an associated mortality rate between 3.5% and 12% in the acute phase1 and residual disability rate of 20% or more. Many other patients are left with long-term fatigue.

Imprenta: Clinical Medicine, v. 10, n. 4, p. 399-401, 2010

Identificador do objeto digital: 10.7861/clinmedicine.10-4-399

Descritores: Guillain-Barre Syndrome - Immunology

Data de publicação: 2010

INDICADORES

ACESSO